WASHINGTON (Reuters) - GlaxoSmithKline has received conditional approval for over-the-counter sales of the weight-loss drug Xenical, a U.S. Food and Drug Administration spokeswoman said on Friday. The British drugmaker received a letter from the FDA on Thursday for the drug, which would be sold under the brand name Alli, FDA spokeswoman Laura Alvey said. She did not say what steps the company must take before it can win final approval.
